Lyra Therapeutics has appointed Harlan W. Waksal as Executive Chairman. Dr. Waksal most recently served as President, Chief Executive Officer and Member of the Board of Directors of Kadmon Holdings prior to its acquisition by Sanofi in November 2021.

With more than 30 years of scientific, clinical development, business development and management experience in the industry, Dr. Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.  

"Harlan brings tremendous experience leading late-stage and commercial biotech and pharmaceutical companies. We look forward to adding his strategic guidance to our leadership team as we advance our novel pipeline candidates, LYR-210 and LYR-220, through the clinic, and aim to transform the treatment paradigm for chronic rhinosinusitis (CRS) patients who have failed medical management," said Maria Palasis , Lyra's President and Chief Executive Officer.